Congratulations to all colleagues involved in the H2020 2017 Health call on the fantastic success which has resulted in 10 projects funded (including one coordinated by the University).
Together these projects help solve significant health problems ranging from Rare Diseases, Prevention and management of alcohol use, Brain tumour research, Gene therapy for immunodeficiency, First ever international academically – driven clinical trial in the field of adoptive transfer of virus-specific T cells, Optimizing response to Li treatment through personalized evaluation of individuals with bipolar I disorder, Computational modelling and breast cancer, Innovative in-silico based approach to improve the efficacy and precision of drug repurposing trials and Drug tracing of protein mutations in cardiomyopathy.
• MCDS-Therapy: Repurposing of carbamazepine for treatment of skeletal dysplasia, Prof Mike Briggs (Institute of Genetic Medicine) – Coordinator, Co-PI Dr Michael Wright (Newcastle upon Tyne Hospitals NHS Foundation Trust/Institute of Genetic Medicine)
• Solve-RD: Solving the unsolved Rare Diseases, Prof Rita Horvath (Institute of Genetic Medicine)
• SCALA: Scale-up of Prevention and Management of Alcohol Use Disorders and Comorbid Depression in Latin America, Dr Amy O’Donnell (Institute of Health & Society), CoIs: Prof Eileen Kaner, Prof Gill Rowlands, Prof Peter Anderson (Institute of Health & Society)
• RECOMB: Stem-cell based gene therapy for recombination deficient SCID (RECOMB) and TRACE: Transfer of multivirus-specific T-cells following transplantation, Dr Andrew Gennery (Institute of Cellular Medicine)
• R-LiNK: Optimizing response to Li treatment through personalized evaluation of individuals with bipolar I disorder: the R-LiNK initiative, Dr David Cousins, Prof Andrew Blamire, Prof Jan Scott, Dr Fiona Smith, Dr Pete Thelwall, Dr Yujiang Wang, Amy-Rose Hayes, Carly Flowers, Joe Necus, Morgan Irving
• MESI-STRAT: Systems Medicine of Metabolic-Signaling Networks: A New Concept for Breast Cancer Patient Stratification, Dr Daryl Shanley (Institute for Cell and Molecular Biosciences), Prof Nicola Curtin (Northern Institute for Cancer Research)
• REPOTRIAL: An in silico-based approach to improve the efficacy and precision of drug REPurpOsing TRIALs for a mechanism-based patient cohort with predominant cerebro-cardiovascular phenotypes, Prof Anil Wipat (School of Computing), Dr Simon Cockell (Bioinformatics Support Unit)
These projects together bring 5.7 million Euro of research grant income into the university and will utilise collaborations with 137 institutions from across the EU and Internationally.
2017 Health call
- Rare diseases
- Alcohol use
- Brain tumours
- Gene therapy
- Virus-specific T-cells
- Li treatment
- Computational modelling and breast cancer
- Drug repurposing
published on: 1st March 2018
If you would like to submit a staff announcement or provide feedback about this website please visit our Contact Us section.